Antibodies and Selection of Monoclonal Antibodies

Abstract

Monoclonal antibodies are universal binding molecules with a high specificity for their target and are indispensable tools in research, diagnostics and therapy. The biotechnological generation of monoclonal antibodies was enabled by the hybridoma technology published in 1975 by Köhler and Milstein. Today monoclonal antibodies are used in a variety of applications as flow cytometry, magnetic cell sorting, immunoassays or therapeutic approaches. First step of the generation process is the immunization of the organism with appropriate antigen. After a positive immune response the spleen cells are isolated and fused with myeloma cells in order to generate stable, long-living antibody-producing cell lines - hybridoma cells. In the subsequent identification step the culture supernatants of all hybridoma cells are screened weekly for the production of the antibody of interest. Hybridoma cells producing the antibody of interest are cloned by limited dilution till a monoclonal hybridoma is found. This is a very time-consuming and laborious process and therefore different selection strategies were developed since 1975 in order to facilitate the generation of monoclonal antibodies. Apart from common automation of pipetting processes and ELISA testing there are some promising approaches to select the right monoclonal antibody very early in the process to reduce time and effort of the generation. In this chapter different selection strategies for antibody-producing hybridoma cells are presented and analysed regarding to their benefits compared to conventional limited dilution technology.

Targeted Radionuclide Therapy of Prostate Cancer—From Basic Research to Clinical Perspectives

“…The patient was treated with two cycles of 213 Bi-PSMA-617 with a cumulative activity of 592 MBq. Restaging with 68 Ga-PSMA PET/CT after 11 months showed a remarkable molecular imaging response. This patient also demonstrated a significant decrease in PSA level.…”

“…The heavy and light chains are held together by S-S bonds forming a Y-shape consisting of constant domains (CH and CL) and variable domains (VH and VL). The two VH and VL domains are highly specific for the target antigen forming the antigen-binding fragment (Fab) [68]. The first published antibody against PSMA was the murine mAb 7E11-C5.3 (capromab) [69].…”

Bladder cancer hunting: A microfluidic paper‐based analytical device

“…The gold-labeled antibody is bound to an antigen to form an immune complex, and similarly, another is used as a detection antibody to capture the immune complex by binding to different sites of the antigen. ELISA experiments are performed here to achieve screening of antibody pairs [43,44]. When the immune complex reaches a certain concentration, it will cause a chromogenic reaction, and more accurate results can be obtained by gray value analysis.…”

Evaluation of Monoclonal Antibody (IgG2bMAb) for Detection of Coproantigen from Experimentally Infected Rats with Strongyloides ratti

“…The monoclonal antibody was developed against the soluble antigen of iL3 larvae of S. ratti [14]. Blood samples were collected every two weeks from the tail vein of each mouse before and after immunisation and were used as controls for positive and negative sera [15,16]. Five to eight weeks old female Balb/c mice were immunised intraperitoneal with 50 µg/mL of the soluble antigen emulsified in Complete Freund's adjuvant (Merck, USA).…”

“…The mouse with the highest antibody titer was selected for the development of hybridoma cells. Parental myeloma cells of Balb/c mice origin, Sp2/0-Ag14 (ATCC® CRL-1581™) was used to stabilize hybridoma cells for the continuous secretion of monoclonal antibodies [15,16]. The cells were cultured in 5 mL of DMEM (Merck, USA), containing 10% fetal bovine serum (Meck, USA) in a 25 cm3 tissue culture flask (Thermoscientific, USA).…”